|
Treatment of Parkinson's Disease with a Transdermal Skin Patch Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Treatment of Parkinson's Disease with a Transdermal Skin Patch conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Treatment of Parkinson's Disease with a Transdermal Skin Patch Clinical research trials and Treatment of Parkinson's Disease with a Transdermal Skin Patch health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Treatment of Parkinson's Disease with a Transdermal Skin Patch. Treatment of Parkinson's Disease with a Transdermal Skin Patch Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Treatment of Parkinson's Disease with a Transdermal Skin Patch clinical trial. Human subjects often get the best healthcare available for their Treatment of Parkinson's Disease with a Transdermal Skin Patch condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Parkinson's Disease with a Transdermal Skin Patch  Treatment of Parkinson's Disease with a Transdermal Skin Patch
Treatment of Parkinson's Disease with a Transdermal Skin Patch
For Condition: Parkinson Disease
Status: Completed
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Muscle tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. This study is designed to determine the effects of a new drug, N-9023. The drug acts like dopamine and can be given through a skin patch (transdermal) for treatment of parkinsonian symptoms. The goals of this study are to find out whether N-9023 is useful in treating the signs and symptoms of Parkinson's disease and to determine the best dose of N-9023 that is safe and effective.
Details: The acute safety and antiparkinsonian efficacy of transdermally delivered N-0923 will be evaluated in patients with Parkinson's disease. This dopamine receptor agonist will be administered transdermally under double-blind conditions, in a rising dose paradigm. Antiparkinsonian activity will be quantified by means of standard rating scales. Possible adverse events will be assessed by appropriate clinical and laboratory tests.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: All patients will carry a diagnosis of Parkinson's Disease based on the presence of a characteristic clinical history and neurological findings. Symptom severity will range from Hoehn & Yahr stage II-IV. Males and females between the ages 30-76 are eligible for the study. Initial emphasis will be on patients who are taking few or no other medications than levodopa for their Parkinson's disease. No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk. No patients with a history of significant cardiac (myocardial infarction within 12 months prior to study, dysrhythmia; QTc intervals greater than 440 msec). No patients who are convulsive, hepatic, or with renal disorders (exceeding the upper limit of normal values for LFT's and creatinine respectively). No patients with evidence of other serious medical illness, a history of alcohol or drug abuse, those who have participated in an investigational trial within 28 days prior to study, and pregnant or nursing women or anyone not practicing effective means of birth control.
Total Enrollment: 20
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990104; 99-N-0104
Study Start Date: May 5, 1999
Record last reviewed: June 22, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001931
Other Parkinson Disease Studies:
1. Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease
2. Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease
3. Phase II Study of Pallidotomy for Parkinson Disease
4. Study of Axial Mobility Exercises in Parkinson Disease
5. Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease
Related Studies:
Other Parkinson Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Treatment of Parkinson's Disease with a Transdermal Skin Patch
|
|
|
|
|
|
|
|
